



Substitute for Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 11617-004-999	APPLICATION NO. 10/538,695
	APPLICANT: Park et al.	
	FILING DATE: June 10, 2005	ART UNIT: CONF. NO.: <del>2817</del> 1615 6982


## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS*		DOCUMENT NUMBER	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Ha	A01	5,451,409	09/19/1995	Rencher et al.	
↑	A02	5,591,452	01/07/1997	Miller et al.	
	A03	5,807,583	09/15/1998	Kristensen et al.	
	A04	5,849,240	12/15/1998	Miller et al.	
	A05	5,891,471	04/06/1999	Miller et al.	
	A06	5,955,104	09/21/1999	Momberger et al.	
	A07	5,965,163	10/12/1999	Miller et al.	
	A08	5,968,551	10/19/1999	Oshlack et al.	
	A09	6,103,261	08/15/2000	Chasin et al.	
	A10	6,143,322	11/07/2000	Sackler et al.	
	A11	6,159,501	12/12/2000	Skinhoj	
	A12	6,162,467	12/19/2000	Miller et al.	
	A13	6,254,887	07/03/2001	Miller et al.	
	A14	6,261,599	07/17/2001	Oshlack et al.	
	A15	6,290,990	09/18/2001	Grabowski et al.	
	A16	6,294,195	09/25/2001	Oshlack et al.	
↓	A17	6,306,438	10/23/2001	Oshlack et al.	
Ha	A18	6,335,033	01/01/2002	Oshlack et al.	

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*		Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
						YES	NO
Ha	B01	WO 93/15753	08/19/1993	Kaken Pharmaceutical Co. Ltd.			X
↑	B02	WO 95/14460	06/01/1995	Euroceltique S.A.			
	B03	WO 98/04249	02/05/1998	Asta Medica Aktiengesellschaft			
	B04	WO 99/47128	09/23/1999	Bristol-Myers Squibb Company			
↓	B05	WO 04/080447	09/23/2004	Euroceltique, S.A.			
Ha	B06	EP 1 125 586	08/22/2001	Tanabe Seiyaku Co., Ltd.			

EXAMINER HASAN S. AHMED	DATE CONSIDERED 22 JANUARY 2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



INFORMATION DISCLOSURE STATEMENT BY APPLICANT  
(Use several sheets if necessary)

ATTY DOCKET NO.

11617-004-999

APPLICATION NO.

10/538,695

APPLICANT:

Park et al.

FILING DATE:

June 10, 2005

ART UNIT: CONF. NO.:

2817.1615 6982

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	DATE MM/DD/YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
					YES	NO

**NON PATENT LITERATURE DOCUMENTS** (include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume, publisher, city and/or country where published., etc.)

EXAMINER'S INITIALS*	Country Code, Number, Kind of Code (if known)	Name of Patentee or Applicant of Cited Document
HA	C01	AIMAN et al., "Controlled release of tramadol hydrochloride from matrices prepared using glyceryl behenate," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2001, 52: 231-235

EXAMINER

HASAN S. AHMED

DATE CONSIDERED

22 JANUARY 2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.